Investigations into chimeric antigen receptor (CAR) T cells, predominantly targeting prostate-specific membrane antigen (PSMA) via multiple phase I/II trials (NCT03089203, NCT03356795), have reported occasional partial responses but face challenges from on-target/off-tumor toxicity and the immunosuppressive tumor microenvironment [85]. Here, FOLH1 is linked to neoplasm.